An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis

Trial Profile

An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2017

At a glance

  • Drugs Infliximab (Primary) ; Infliximab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Celltrion
  • Most Recent Events

    • 29 Oct 2017 According to a Celltrion media release, data were presented at the 25th United European Gastroenterology (UEG) Week.
    • 09 May 2017 Planned primary completion date changed from 1 Jul 2017 to 23 Feb 2019.
    • 09 May 2017 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top